Faron Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Clevegen (bexmarilimab) / Faron Pharma
2021-002104-12: A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 (bexmarilimab) in haematological malignancies in combination with azacitidine or azacitidine and venetoclax

Not yet recruiting
1/2
271
Europe
FP-1305, Concentrate for solution for infusion
Faron Pharmaceuticals Ltd., Faron Pharmaceuticals Ltd
-Myelodysplastic Syndrome-Chronic Myelomonocytic Leukemia-Acute Myeloid Leukemia, Advanced haematological malignancies, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
MATINS, NCT03733990 / 2018-002732-24: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

Completed
1/2
216
Europe, US
FP-1305 (bexmarilimab), bexmarilimab
Faron Pharmaceuticals Ltd
Cancer
09/23
10/23
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Active, not recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
04/26
04/26
NCT05171062: Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Withdrawn
1
36
US
bexmarilimab (FP-1305), FP-1305, Pembrolizumab, Keytruda
The University of Texas Health Science Center at San Antonio, Faron Pharmaceuticals Ltd
Non-small Cell Lung Cancer
12/25
12/26
Traumakine (IFN beta-1a) / Faron Pharma, Maruishi Pharma
Faron Pharma_COVID_T: Faron Pharmaceuticals drug accepted to global pneumonia programme

Not yet recruiting
3
0
Asia-Pacific, Europe and North America
Traumakine
Faron Pharma, Maruishi Pharma
Coronavirus (COVID-19)
 
 
Faron Pharma_COVID_Traumakine: Faron Pharmaceuticals drug accepted to global pneumonia programme

Recruiting
3
0
Asia-Pacific, Europe and North America
Traumakine
Faron Pharma, Maruishi Pharma
Coronavirus (COVID-19)
 
 
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Withdrawn
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Clevegen (bexmarilimab) / Faron Pharma
2021-002104-12: A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 (bexmarilimab) in haematological malignancies in combination with azacitidine or azacitidine and venetoclax

Not yet recruiting
1/2
271
Europe
FP-1305, Concentrate for solution for infusion
Faron Pharmaceuticals Ltd., Faron Pharmaceuticals Ltd
-Myelodysplastic Syndrome-Chronic Myelomonocytic Leukemia-Acute Myeloid Leukemia, Advanced haematological malignancies, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
MATINS, NCT03733990 / 2018-002732-24: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

Completed
1/2
216
Europe, US
FP-1305 (bexmarilimab), bexmarilimab
Faron Pharmaceuticals Ltd
Cancer
09/23
10/23
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Active, not recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
04/26
04/26
NCT05171062: Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Withdrawn
1
36
US
bexmarilimab (FP-1305), FP-1305, Pembrolizumab, Keytruda
The University of Texas Health Science Center at San Antonio, Faron Pharmaceuticals Ltd
Non-small Cell Lung Cancer
12/25
12/26
Traumakine (IFN beta-1a) / Faron Pharma, Maruishi Pharma
Faron Pharma_COVID_T: Faron Pharmaceuticals drug accepted to global pneumonia programme

Not yet recruiting
3
0
Asia-Pacific, Europe and North America
Traumakine
Faron Pharma, Maruishi Pharma
Coronavirus (COVID-19)
 
 
Faron Pharma_COVID_Traumakine: Faron Pharmaceuticals drug accepted to global pneumonia programme

Recruiting
3
0
Asia-Pacific, Europe and North America
Traumakine
Faron Pharma, Maruishi Pharma
Coronavirus (COVID-19)
 
 
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Withdrawn
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27

Download Options